Sana Biotechnology (NASDAQ:SANA – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01, FiscalAI reports.
Sana Biotechnology Price Performance
SANA traded up $0.05 during trading on Monday, reaching $3.56. 2,257,941 shares of the company’s stock were exchanged, compared to its average volume of 2,769,045. Sana Biotechnology has a 1 year low of $1.60 and a 1 year high of $6.55. The stock has a market capitalization of $961.16 million, a P/E ratio of -3.67 and a beta of 2.17. The company’s fifty day simple moving average is $3.36 and its 200-day simple moving average is $4.04.
Wall Street Analysts Forecast Growth
A number of research firms have recently weighed in on SANA. Rodman & Renshaw began coverage on shares of Sana Biotechnology in a report on Monday. They issued a “buy” rating and a $16.00 price target on the stock. Zacks Research lowered shares of Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 3rd. Wall Street Zen raised shares of Sana Biotechnology from a “strong sell” rating to a “sell” rating in a research report on Saturday. Morgan Stanley reaffirmed an “overweight” rating and issued a $12.00 price objective on shares of Sana Biotechnology in a research report on Friday, March 13th. Finally, Wedbush increased their price objective on shares of Sana Biotechnology from $6.00 to $7.00 and gave the company an “outperform” rating in a research report on Tuesday, April 14th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Sana Biotechnology currently has an average rating of “Moderate Buy” and a consensus target price of $9.50.
Hedge Funds Weigh In On Sana Biotechnology
Institutional investors have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Sana Biotechnology during the 3rd quarter worth approximately $175,000. Virtu Financial LLC raised its position in Sana Biotechnology by 82.2% during the 3rd quarter. Virtu Financial LLC now owns 41,224 shares of the company’s stock worth $146,000 after buying an additional 18,598 shares during the last quarter. Atom Investors LP purchased a new position in Sana Biotechnology during the 4th quarter worth approximately $124,000. LPL Financial LLC purchased a new position in Sana Biotechnology during the 4th quarter worth approximately $104,000. Finally, Polymer Capital Management US LLC raised its position in Sana Biotechnology by 32.5% during the 4th quarter. Polymer Capital Management US LLC now owns 18,285 shares of the company’s stock worth $74,000 after buying an additional 4,480 shares during the last quarter. 88.23% of the stock is owned by hedge funds and other institutional investors.
Sana Biotechnology Company Profile
Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.
The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.
Featured Stories
- Five stocks we like better than Sana Biotechnology
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Sana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
